A real-world study of sorafenib and lenvatinib: A retrospective review of multikinase inhibitor therapies for hepatocellular carcinoma in an Australian tertiary treatment center

被引：0
|
作者：
Patwala, K. [1 ]
Alam, W. [1 ]
Ng, S. [1 ]
O'Neill, P. [1 ]
Mishra, G. [1 ]
Bell, S. [1 ]
Dev, A. [1 ,2 ]
机构：
[1] Monash Hlth, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
368
引用
收藏
页码：97 / 98
页数：2
相关论文
共 50 条
  • [41] A real-world study of camrelizumab in the treatment of hepatocellular carcinoma.
    Zeng, Yong-Yi
    Guo, Wu-hua
    Zhang, Zhibo
    Shi, Xi
    Su, Yongjie
    Cai, Qinghe
    Peng, Jianyang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Multicenter, real-world experience with lenvatinib for patients with advanced hepatocellular carcinoma in Japan
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Nakai, Masato
    Morikawa, Kenichi
    Sakamoto., Naoya
    JOURNAL OF HEPATOLOGY, 2020, 73 : S909 - S909
  • [43] Treatment outcomes with sorafenib in advanced hepatocellular carcinoma: A single-center retrospective study
    Prejac, J.
    Tomek, D.
    Kekez, D.
    Majerovic, M.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S194 - S194
  • [44] Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study
    Zhong, Jian-Hong
    Peng, Ning-Fu
    You, Xue-Mei
    Ma, Liang
    Xiang, Xiao
    Wang, Yan-Yan
    Gong, Wen-Feng
    Wu, Fei-Xiang
    Xiang, Bang-De
    Li, Le-Qun
    ONCOTARGET, 2017, 8 (11) : 18296 - 18302
  • [45] Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study
    Wei, Ning
    Lu, Dong
    Zhou, Chunze
    Cheng, Delei
    Zhang, Zhengfeng
    Zhang, Xingming
    Xiao, Jingkun
    Lv, Weifu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array
    Sato, Yasushi
    Tomonari, Tetsu
    Tanaka, Hironori
    Tanaka, Takahiro
    Hirao, Akihiro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Kagiwada, Harumi
    Kitazawa, Masashi
    Fukui, Kazuhiko
    Horimoto, Katsuhisa
    Takayama, Tetsuji
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [47] Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
    Zou, Jixue
    Huang, Peixin
    Ge, Ningling
    Xu, Xin
    Wang, Yanhong
    Zhang, Lan
    Chen, Yi
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 1898 - 1906
  • [48] Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
    Horger, Marius
    Lauer, Ulrich M.
    Schraml, Christina
    Berg, Christoph P.
    Koppenhoefer, Ursula
    Claussen, Claus D.
    Gregor, Michael
    Bitzer, Michael
    BMC CANCER, 2009, 9
  • [49] Real-world efficacy and safety of donafenib-based therapies in patients with unresectable hepatocellular carcinoma: A retrospective study.
    Shang, Changzhen
    Luo, Xuan
    Zhong, Jinyi
    Zhang, Jianlong
    Li, Huilong
    Tan, Wenliang
    Lei, Zhang
    Chen, Yajin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
    Marius Horger
    Ulrich M Lauer
    Christina Schraml
    Christoph P Berg
    Ursula Koppenhöfer
    Claus D Claussen
    Michael Gregor
    Michael Bitzer
    BMC Cancer, 9
12345